Login
Join
FOLLOW:
Subscribe Free
Magazine
eNewsletter
Checkout
Menu
Magazine
News
Manufacturing
Packaging
Development
Compliance
Top 20
Directory
Microsites
Events
More
Magazine
News
Manufacturing
Packaging
Development
Compliance
Top 20
Directory
Microsites
Events
Current / Back Issue
Features
Editorial
Columns
Digital Edition
eNewsletter Archive
Our Team
Editorial Guidelines
Subscribe Now
Advertise Now
Top Features
SARS-CoV-2 R&D: Is It Over?
Sustainability: A New Threat or Opportunity for CDMOs?
Advanced Therapy Manufacturing
Advanced Therapy Packaging Trends
CEO Spotlight: Darren Head
Breaking News
Online Exclusives
Industry News
Collaborations & Alliances
Promotions & Moves
Trials & Filings
Financial Reports
Bio News & Views
Custom Sourcing News
Packaging & Tracking
CRO News
Live From Shows
Top News
Piramal Pharma Solutions New API Plant in Canada Now Online
MG America Appoints Claudio Radossi as President
Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
Sartorius Expands Manufacturing Site in Tunisia
BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
APIs
Aseptic Processing
Cleaning Validation
Clinical Trial Materials
Cytotoxics and High Potency Manufacturing
Equipment
Excipients
Extractables and Leachables
Facilities
Fill/Finish
Lyophilization
Parenterals
Process Development
Process Validation
Risk Management
Scale-up/ Technology Transfer
Solid Dosage/ Creams/ Ointments
Piramal Pharma Solutions New API Plant in Canada Now Online
Selecting a CMO Partner for Sterile Injectable Manufacturing
Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
Grand Opening of Kodiak Sciences’ Bioconjugation Facility
Vertex Expands Cell and Gene Therapy Footprint
Capsules
Cold Chain Management
Injectables
Logistics
Serialization
Solid Dosage / Semi-solids
Supply Chain
Vials
Selecting a CMO Partner for Sterile Injectable Manufacturing
Royalty Pharma and Jefferies Invest $111M in ApiJect
Cryoport Acquires Cell&Co BioServices for €6.2M
Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery
Yourway Adds Capacity for Controlled Ambient Storage
Analytical Services
Bioanalytical Services
Bioassay Developement
Biologics, Proteins, Vaccines
Biosimilars
Chemistry
Clinical Trials
Drug Delivery
Drug Development
Drug Discovery
Formulation Development
Information Technology
Laboratory Testing
Methods Development
Microbiology
Preclinical Outsourcing
R&D
Toxicology
Selecting a CMO Partner for Sterile Injectable Manufacturing
BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
WCG Appoints Sam Srivastava CEO
AffyXell Expands Manufacturing Partnership with GenScript ProBio
ABL and Odimma Therapeutics Enter Development Agreement
Filtration & Purification
GMPs/GCPs
Inspections
QA/QC
Regulatory Affairs
Validation
FDA Inspection Trends Update
Phase-Appropriate cGMP Considerations for Cell and Gene Therapy
Sustainability: A New Threat or Opportunity for CDMOs?
In Pursuit of Sustainability: How the Biopharma Industry Can Contribute
Conducting Clinical Trials During the Pandemic: What Did We Learn?
Companies
Categories
Corporate Capabilities
Add New Company
Contract Service Directory Companies
Qosina
Kyongbo Pharmaceutical
IDT Biologika
Vector Partners Limited
CMC Pharmaceuticals
Companies
News Releases
Posters
Brochures
Services
Videos
Case Study
White Papers
Jobs
Contract Service Directory Companies
Qosina
Kyongbo Pharmaceutical
IDT Biologika
Vector Partners Limited
CMC Pharmaceuticals
Webinars
Live From Shows
Magazine
Current / Back Issue
Features
Editorial
Columns
Editorial Guidelines
Subscribe Now
Advertise Now
Enewsletter Archive
Digital Edition
Directory
Companies
Categories
Corporate Capabilities
Add Your Company
Manufacturing
APIs
Aseptic Processing
Cleaning Validation
Clinical Trial Materials
Cytotoxics and High Potency Manufacturing
Equipment
Excipients
Extractables and Leachables
Facilities
Fill/Finish
Lyophilization
Parenterals
Process Development
Process Validation
Risk Management
Scale-up/ Technology Transfer
Solid Dosage/ Creams/ Ointments
cGMP Manufacture
Packaging
Capsules
Cold Chain Management
Injectables
Logistics
Serialization
Solid Dosage / Semi-solids
Supply Chain
Vials
Development
Analytical Services
Bioanalytical Services
Bioassay Developement
Biologics, Proteins, Vaccines
Biosimilars
Chemistry
Clinical Trials
Drug Delivery
Drug Development
Drug Discovery
Formulation Development
Information Technology
Laboratory Testing
Methods Development
Microbiology
Preclinical Outsourcing
R&D
Toxicology
Compliance
Filtration & Purification
GMPs/GCPs
Inspections
QA/QC
Regulatory Affairs
Validation
Top 25 Pharma & BioPharma
Contract Pharma Direct
Breaking News
Online Exclusives
Slideshows
Experts Opinions
Surveys
Outsourcing Survey
Salary Survey
Glossary
Videos
White Papers
Podcasts
Infographics
Supplier Microsite
Companies
News Releases
Posters
Brochures
Services
Videos
Case Study
White Papers
Contract Pharma Conference
Contract Pharma Conference
Speakers
Exhibitors
Conference Sessions
eBook
Webinars
Events
Industry Events
Live from Show Events
Webinars
Classifieds / Job Bank
Classifieds
Job Bank
About Us
About Us
Contact Us
Advertise With Us
Privacy Policy
Terms of Use
Cytotoxics and High Potency Manufacturing
All
APIs
Aseptic Processing
cGMP Manufacture
Cleaning Validation
Clinical Trial Materials
Cytotoxics and High Potency Manufacturing
Excipients
Extractables and Leachables
Facilities
Fill/Finish
Lyophilization
Parenterals
Process Development
Process Validation
Risk Management
Scale-up/Technology Transfer
Solid Dosage/Creams/Ointments
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
|
Solid Dosage/Creams/Ointments
Bora Pharmaceuticals to Expand Operations
Will invest $10 million in oral solid dose capabilities across facilities in Taiwan and Canada.
04.21.22
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
Aenova Invests in New Building for the Production of Highly Potent Drugs
Increases production capacity to meet market demand with an investment of roughly €10 million at Regensburg site.
04.11.22
APIs
|
Breaking News
|
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
AGC to Expand Synthetic Pharmaceutical Production in Spain
$100 million investment will increase current production capacity by 30% and include facilities for HPAPIs.
04.08.22
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Fill/Finish
|
Parenterals
|
Vials
Manufacturing Equipment Evolves to Address Today's Production Needs
Dr. Andreas Mattern, VP Strategy & Global Product Management Pharma at Syntegon discusses some of the latest advances in manufacturing equipment.
Online Exclusives
Kristin Brooks, Managing Editor, Contract Pharma
04.07.22
APIs
|
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
Lonza Expands API Development and Manufacturing Laboratories in Nansha, China
Will provide additional early-phase highly-potent API manufacturing capabilities.
03.08.22
APIs
|
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
Olon Expands High Containment API Operations
The CDMO plans to invest €27 million over the next two years including a newly commissioned production line.
02.09.22
Breaking News
|
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Drug Development
|
Formulation Development
|
Industry News
Adare Pharma Solutions Acquires Frontida BioPharm
Expands CDMO offerings to include new capabilities such as high potency compound handling and packaging services.
12.01.21
APIs
|
Breaking News
|
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Excipients
|
Industry News
CordenPharma Invests €9.7M in New CTD Facility at Plankstadt CoE
To design and install GMP Clinical Trial Development facility for the manufacture of oral solid dosage drug products.
11.30.21
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
Micro-Sphere Expands Capabilities with $3.5M Investment
Swiss CDMO invests in powder containment and extends spray drying capabilities.
11.08.21
APIs
|
Breaking News
|
Cytotoxics and High Potency Manufacturing
FLAMMA USA Completes Commissioning of HPAPI Suite
Flamma has undergone an extensive qualification of the HPAPI suite over the past six months in order to bring this offering to the marketplace.
11.01.21
APIs
|
Biologics, Proteins, Vaccines
|
Breaking News
|
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Industry News
MilliporeSigma Launches New Tech and Expanded ADC Capacity
ChetoSensar technology improves ADC solubility, to enhance ADC capabilities at clinical manufacturing facility in St. Louis, MO.
10.28.21
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Industry News
Ardena Acquires Idifarma from Suanfarma and Sodena
Adds spray drying technology and high potency capabilities.
09.02.21
Breaking News
|
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Industry News
Lonza Extends Large-Scale MAb Commercial Supply Pact
To provide commercial-scale manufacture of monoclonal antibodies under a long-term agreement at Visp site.
07.19.21
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Industry News
|
Solid Dosage/Creams/Ointments
Idifarma Launches Accelerated Pathway for Complex Drugs
‘Simply to Clinic’ leverages expertise in oral standard and highly potent drugs to take projects from pre-formulation to clinical trials.
07.14.21
APIs
|
Cytotoxics and High Potency Manufacturing
|
Drug Development
Leverage the Benefits of Biocatalysis with the Right API CDMO
A powerful tool for organic synthesis, enzymatic chemistry has become an established methodology for manufacturing APIs.
Biologics, Proteins, Vaccines
|
Breaking News
|
Collaborations & Alliances
|
Cytotoxics and High Potency Manufacturing
|
Industry News
Novasep, Exelixis Ink ADC Manufacturing Agreement
Covers the cGMP clinical manufacturing of a next-generation ADC drug candidate.
07.06.21
APIs
|
Breaking News
|
cGMP Manufacture
|
Cytotoxics and High Potency Manufacturing
|
Industry News
Lonza Expands API Development, Mfg. Facility in China
20M CHF investment will include three 1,000L GMP trains and new development and GMP labs with HPAPI capabilities.
06.28.21
APIs
|
Cytotoxics and High Potency Manufacturing
|
Formulation Development
|
Process Development
Solubility Enhancement of Hydrophobic Drugs and APIs Using Hot Melt Extrusion
Efficient processing and production technology for solid molecular dispersion, HME can provide sustained, modified and targeted drug delivery.
Ameya Deshpande, Formulation Scientist, Avomeen
05.25.21
Bio News
|
Breaking News
|
cGMP Manufacture
|
Collaborations & Alliances
|
Cytotoxics and High Potency Manufacturing
|
Industry News
Avid Bioservices to Manufacture Zynlonta for ADC Therapeutics
Zynlonta is an antibody drug conjugate approved for cancer treatment.
Charles Sternberg, Assistant Editor
05.25.21
Breaking News
|
Cytotoxics and High Potency Manufacturing
|
Facilities
|
Industry News
Novasep Expands HPAPI Manufacturing Capacity
Responds to increasing customer demand for manufacturing services for antibody drug conjugates.
Tim Wright, Editor, Contract Pharma
05.13.21
Trending
Royalty Pharma and Jefferies Invest $111M in ApiJect
Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
Piramal Pharma Solutions New API Plant In Canada Now Online | Contract Pharma
Biopharma Manufacturing Facility Construction | Contract Pharma
Next-Gen Lab Services | Contract Pharma
Breaking News
Piramal Pharma Solutions New API Plant in Canada Now Online
MG America Appoints Claudio Radossi as President
Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
Sartorius Expands Manufacturing Site in Tunisia
BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
View Breaking News >
CURRENT ISSUE
May 2022
Sustainability and the Biopharma Industry
Contract Manufacturing During COVID
Orphan Drugs in the United States
CEO Spotlight: Peter DeYoung
CEO Spotlight: Darren Head
Advanced Therapy Packaging Trends
Advanced Therapy Manufacturing
Sustainability: A New Threat or Opportunity for CDMOs?
SARS-CoV-2 R&D